Does tumor stroma ratio of breast cancer trucut biopsy determine response to neoadjuvant therapy?

Simple item page
dc.contributor.authorMallya, Ven_US
dc.contributor.authorSingh, Ven_US
dc.contributor.authorKaur, Nen_US
dc.contributor.authorYadav, Pen_US
dc.contributor.authorMandal, Sen_US
dc.contributor.authorKhurana, Nen_US
dc.contributor.authorLal, Pen_US
dc.date.accessioned2020-04-10T01:51:22Z
dc.date.available2020-04-10T01:51:22Z
dc.date.issued2020-02
dc.description.abstractAims and Objectives: We examined the prognostic value of Tumor stroma ratio (TSR) in breast tumor core biopsy (TCB) specimen to determine response to neoadjuvant therapy (NAT) prior to modified radical mastectomy (MRM). Methods: This was a retrospective analysis of patients with breast cancer who underwent TCB before NAT between August 2016 and July 2018. TSR in TCB was studied independently by 2 pathologists ( VM, VS) defined as stroma rich (TSR?50%) or stroma poor (TSR>50%). MRM specimen of these patients were subsequently studied .Residual cancer burden (RCB) was calculated using the MD Anderson RCB calculator, categorized as complete (0), good (1) Partial (2) and no response (3). Statistical analysis was done to assess correlation of TSR to RCB. Results: A total of 62 patients were analyzed. Mean(SD) age was 48(11) years.Twenty eight (45%) and 34 (55%) patients were stroma rich and stroma poor respectively. Twenty six (42%) patients were responders and 36 (58%) non-responders to NAT. Among stroma rich patients, only 3 (10%) were responders (Class 0 &1)and 25 (90%) non-responders(Class2&3)to NAT, among stroma poor patients 23 (68%) responded well and 11 (32%) did not.TSR had a moderate negative correlation with RCB (-0.6). On univariate analysis, only TSR had a significant effect on RCB class (<0.001). Conclusions: TSR on TCB is a useful prognostic factor to determine response of breast carcinoma patients to neoadjuvant therapy.It is cost effective, simple and quick. Larger multi-centric studies would be useful to study its clinical implications.en_US
dc.identifier.affiliationsDepartment of Pathology, Maulana Azad Medical College, New Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Surgery, Maulana Azad Medical College, New Delhi, Indiaen_US
dc.identifier.citationMallya V, Singh V, Kaur N, Yadav P, Mandal S, Khurana N, Lal P. Does tumor stroma ratio of breast cancer trucut biopsy determine response to neoadjuvant therapy?. Indian Journal of Pathology and Microbiology. 2020 Feb; 63(5): 113-116en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/196476
dc.languageenen_US
dc.publisherIndian Association of Pathologists and Microbiologistsen_US
dc.relation.issuenumber5en_US
dc.relation.volume63en_US
dc.source.urihttps://dx.doi.org/10.4103/IJPM.IJPM_793_18en_US
dc.subjectBreasten_US
dc.subjectneoadjuvant chemotherapyen_US
dc.subjectresidual cancer burdenen_US
dc.subjecttumor stroma ratioen_US
dc.titleDoes tumor stroma ratio of breast cancer trucut biopsy determine response to neoadjuvant therapy?en_US
dc.typeJournal Articleen_US
Files
Collections
Indian Journal of Pathology & Microbiology